{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:37:46Z","timestamp":1788910666596,"version":"build-2803163510"},"reference-count":96,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T00:00:00Z","timestamp":1684627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jtha.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T20:56:27Z","timestamp":1684788987000},"page":"3033-3044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-6418","authenticated-orcid":false,"given":"Leonard A.","family":"Valentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-0675","authenticated-orcid":false,"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7213-998X","authenticated-orcid":false,"given":"Roland W.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-4304","authenticated-orcid":false,"given":"Nigel S.","family":"Key","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9997-454X","authenticated-orcid":false,"given":"Allyson M.","family":"Pishko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5379","authenticated-orcid":false,"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6772-4140","authenticated-orcid":false,"given":"Benjamin J.","family":"Samelson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2410-6312","authenticated-orcid":false,"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.05.011_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.13137","article-title":"New findings on inhibitor development: from registries to clinical studies","volume":"23","author":"Peyvandi","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.05.011_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.05.011_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1537-2995.1989.29589284147.x","article-title":"Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC","volume":"29","author":"Ragni","year":"1989","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2023.05.011_bib6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/hae.12178","article-title":"Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study","volume":"19","author":"Gringeri","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D\u2019Angiolella","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2023.05.011_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1046\/j.1365-2516.2001.00484.x","article-title":"Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia","volume":"7","author":"Soucie","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib9","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10198-021-01339-4","article-title":"Costs and management of patients with hemophilia A in France: the Hemraude study","volume":"23","author":"Laurendeau","year":"2022","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jtha.2023.05.011_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"Walsh","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2023.05.011_bib12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2516.2011.02713.x","article-title":"Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008","volume":"18","author":"Guh","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2516.2011.02692.x","article-title":"Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008","volume":"18","author":"Guh","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib14","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/hae.12621","article-title":"Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment","volume":"21","author":"Earnshaw","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib15","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2023.05.011_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib17","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1111\/hae.13032","article-title":"Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein","volume":"22","author":"Ragni","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib18","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1111\/hae.13064","article-title":"Extended half-life factor VIII for immune tolerance induction in haemophilia","volume":"22","author":"Malec","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib19","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.2021013563","article-title":"First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results","volume":"139","author":"K\u00f6nigs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057018","article-title":"AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors","volume":"12","author":"Matsushita","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtha.2023.05.011_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17474086.2021.1875817","article-title":"Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors","volume":"14","author":"Carcao","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2023.05.011_bib22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"Batsuli","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2516.2007.01584.x","article-title":"Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor","volume":"14","author":"Klarmann","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0037-1617018","article-title":"ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor","volume":"29","author":"Beutel","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2023.05.011_bib25","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1073\/pnas.0912181107","article-title":"Oral delivery of bioencapsulated coagulation\u00a0factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice","volume":"107","author":"Verma","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.05.011_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ymthe.2016.11.009","article-title":"Oral tolerance induction in hemophilia B dogs fed with transplastomic lettuce","volume":"25","author":"Herzog","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib27","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1182\/blood-2004-11-4274","article-title":"Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins","volume":"105","author":"Lei","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib28","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/jth.12576","article-title":"Long-term tolerance to factor VIII is achieved by administration of interleukin-2\/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII","volume":"12","author":"Liu","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/hae.14573","article-title":"CTLA4-Ig prevents development of neutralizing antibody formation after continuous treatment with human FVIII in HA rats","volume":"28","author":"\u00d8vlisen","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib30","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/jth.15497","article-title":"Tolerogenic form of factor VIII to prevent inhibitor development in the treatment of hemophilia A","volume":"19","author":"Nguyen","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cellimm.2015.11.004","article-title":"Tolerogenic nanoparticles to induce immunologic tolerance: prevention and reversal of FVIII inhibitor formation","volume":"301","author":"Zhang","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2023.05.011_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1160\/TH16-05-0404","article-title":"Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin","volume":"117","author":"Biswas","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib33","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1089\/hum.2017.016","article-title":"Gene delivery of activated factor VII using alternative adeno-associated virus serotype improves hemostasis in hemophiliac mice with FVIII inhibitors and adeno-associated virus neutralizing antibodies","volume":"28","author":"Sun","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational potential of immune tolerance induction by AAV liver-directed factor VIII gene therapy for hemophilia A","volume":"11","author":"Samelson-Jones BJ Arruda","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.05.011_bib35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.blre.2018.02.003","article-title":"Review of immune tolerance induction in hemophilia A","volume":"32","author":"Schep","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2023.05.011_bib36","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.13331","article-title":"Gene therapy for immune tolerance induction in hemophilia with inhibitors","volume":"14","author":"Arruda","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cellimm.2015.10.001","article-title":"In\u00a0vivo induction of regulatory T cells for immune tolerance in hemophilia","volume":"301","author":"Wang","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2023.05.011_bib38","first-page":"9","article-title":"Thrombosis complicating non-factor therapy for hemophilia","author":"Ragni","year":"2021","journal-title":"Med Res Arch"},{"key":"10.1016\/j.jtha.2023.05.011_bib39","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/s-0029-1245105","article-title":"The multifactorial etiology of inhibitor development in hemophilia: genetics and environment","volume":"35","author":"Gouw","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib40","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib41","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1182\/blood-2012-06-434803","article-title":"The polygenic nature of inhibitors in hemophilia A: results from the hemophilia inhibitor genetics study (HIGS) combined cohort","volume":"121","author":"Astermark","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cellimm.2015.11.008","article-title":"War and peace: factor VIII and the adaptive immune response","volume":"301","author":"Georgescu","year":"2016","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2023.05.011_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142906","article-title":"B\u00a0cell-activating factor modulates the factor VIII immune response in hemophilia A","volume":"131","author":"Doshi","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2023.05.011_bib44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2516.2009.02122.x","article-title":"New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development","volume":"16","author":"Kurnik","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib45","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1160\/TH14-01-0078","article-title":"Rituximab for treatment of inhibitors in haemophilia A. A phase II study","volume":"112","author":"Leissinger","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib47","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/jth.14740","article-title":"Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors","volume":"18","author":"Doshi","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/hae.14431","article-title":"Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors","volume":"28","author":"Di Minno","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib49","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12185-022-03359-z","article-title":"Longitudinal profiling of anti-factor VIII antibodies in Japanese patients with congenital hemophilia A during factor VIII replacement and immune-tolerance induction therapy","volume":"116","author":"Yoshimura","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2023.05.011_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12695","article-title":"Impact of novel hemophilia therapies around the world","volume":"6","author":"Ozelo","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib51","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/hae.14381","article-title":"Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update","volume":"27","author":"Hart","year":"2021","journal-title":"Haemophilia"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2023.05.011_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13445","article-title":"Immune tolerance induction: what have we learned over time?","volume":"24","author":"Brackmann","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12586","article-title":"The intersection of vector biology, gene therapy, and hemophilia","volume":"5","author":"Lisowski","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib54","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/lt.20519","article-title":"Changes in liver volume from birth to adulthood: a meta-analysis","volume":"11","author":"Johnson","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jtha.2023.05.011_bib55","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood.2021014735","article-title":"Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A","volume":"140","author":"Batty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib56","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","article-title":"Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors","volume":"7","author":"Coppola","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037671","article-title":"Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy","volume":"7","author":"Sack","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2023.05.011_bib58","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1182\/bloodadvances.2021006359","article-title":"Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice","volume":"6","author":"Lundgren","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.05.011_bib59","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2010.240","article-title":"Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors","volume":"19","author":"Sabatino","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib60","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/hum.2006.17.427","article-title":"Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice","volume":"17","author":"Sarkar","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib61","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/mt.2010.170","article-title":"Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application","volume":"18","author":"Monahan","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib62","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","article-title":"Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib63","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib64","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib65","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in\u00a0vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2023.05.011_bib66","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jtha.2023.05.011_bib67","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib68","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib69","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib70","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.05.011_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.12.002","article-title":"Liver induced transgene tolerance with AAV vectors","volume":"342","author":"Keeler","year":"2019","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtha.2023.05.011_bib72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/156652309787909490","article-title":"Hepatic gene transfer as a means of tolerance induction to transgene products","volume":"9","author":"LoDuca","year":"2009","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib73","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2019.12.008","article-title":"Immune response mechanisms against AAV vectors in animal models","volume":"17","author":"Martino","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.05.011_bib74","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/blood-2009-04-214569","article-title":"In\u00a0vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance","volume":"114","author":"Annoni","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib75","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.ymthe.2017.04.029","article-title":"A\u00a0novel platform for immune tolerance induction in hemophilia A mice","volume":"25","author":"Merlin","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib76","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.2022016530","article-title":"Immune complications and their management in inherited and acquired bleeding disorders","volume":"140","author":"Arruda","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib77","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood-2004-03-0847","article-title":"Induction of antigen-specific CD4+ T-cell anergy and deletion by in\u00a0vivo viral gene transfer","volume":"104","author":"Dobrzynski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib78","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1073\/pnas.0508685103","article-title":"Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells","volume":"103","author":"Dobrzynski","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.05.011_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.83","article-title":"Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer","volume":"3","author":"Perrin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.05.011_bib80","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23043","article-title":"Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver","volume":"50","author":"Breous","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2023.05.011_bib81","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in\u00a0vivo gene transfer","volume":"110","author":"Cao","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib82","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/mt.2013.94","article-title":"The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer","volume":"21","author":"Faust","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib83","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3389\/fimmu.2020.01293","article-title":"B\u00a0cell depletion eliminates FVIII memory B cells and enhances AAV8-coF8 immune tolerance induction when combined with rapamycin","volume":"11","author":"Biswas","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2023.05.011_bib84","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.ymthe.2022.07.005","article-title":"IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice","volume":"30","author":"Butterfield","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib85","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ymthe.2019.10.005","article-title":"Liver gene therapy: reliable and durable?","volume":"27","author":"Herzog","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.05.011_bib86","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/hae.14391","article-title":"Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A","volume":"27","author":"Pasi","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","article-title":"International workshop on immune tolerance induction: consensus recommendations","volume":"13","author":"DiMichele","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib88","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12730","article-title":"International Immune Tolerance Induction Study Investigators. US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors","volume":"21","author":"Valentino","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.05.011_bib89","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3324\/haematol.2018.189852","article-title":"Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms","volume":"103","author":"Georgescu","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.05.011_bib90","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.omtm.2020.05.001","article-title":"Timing of intensive immunosuppression impacts risk of transgene antibodies after AAV gene therapy in nonhuman primates","volume":"17","author":"Samelson-Jones","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2023.05.011_bib91","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.05.011_bib92","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1538-7836.2012.04791.x","article-title":"Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity","volume":"10","author":"Kuether","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib93","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1038\/ncomms3773","article-title":"Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A","volume":"4","author":"Du","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2023.05.011_bib94","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/jth.13800","article-title":"Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated","volume":"15","author":"Chen","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.05.011_bib96","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jgm.1442","article-title":"Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A","volume":"12","author":"Ide","year":"2010","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.jtha.2023.05.011_bib98","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/hae.12608","article-title":"Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres","volume":"21","author":"Nakar","year":"2015","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623004245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623004245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:40:32Z","timestamp":1761536432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623004245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":96,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1538783623004245"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.05.011","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}